Pharmaceuticals

FDA expands indication of BioMarin’s Brineura to children with neuronal ceroid lipofuscinosis type 2

bexib
By bexib 0 Min Read

The expanded indication for Brineura allows for the treatment of neuronal ceroid lipofuscinosis type 2 in both symptomatic and pre-symptomatic children.

You Might Also Like

BHF HIF funds over £800,000 to five heart research projects

10-minute brain scan could improve diagnosis of childhood brain tumors

Pharma Pulse July 29, 2024: Why multimodal data is growing in pharma, specialty pharma trends continue to rise, and more

FDA approves Merck’s Keytruda in combination with carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer

Counterfeit Weight Loss Pills and Potential Health Risks

Share This Article
Previous Article More poverty for the poor
Next Article Dogecoin poised for 1,700% rally as it mirrors past cycles: Analyst – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

SUMSUB starts Australian DVS verification of safe ID check
Fintech
Indian cash -free payments secure the $ 53 million US funded by PUBG Publisher Krafton.
Fintech
Late onboarding promotes clients’ losses at Singapore banks.
Fintech
The gorgeous spa Hotelgal Goma Resort will join the elegant hotel collection as the first member of the North Ireland
Hospitality & Tourism